UBS analyst Navin Jacob reinstated coverage of Teva Pharmaceutical with a Buy rating and $22 price target. The U.S. generic industry is on a path to recovery, Jacob tells investors in a research note, citing his firm’s generic price erosion tracker data. The analyst sees 30% potential upside and views Teva’s 2019 guidance as a “hiccup.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.